Impact of Dialysis Modality on Hepcidin and Iron Metabolism

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-11-30

Study Completion Date

2016-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

* Dialysis modality may influence the oxidative stress and proinflammatory cytokines in ESRD patients.
* Dialysis modality may affect hepcidin
* Dialysis modality may influence iron and ESA requirements.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Mode of Dialysis Therapy and Outcomes in End Stage Renal Disease (ESRD)

NCT00931970

End-Stage Renal Disease

UNKNOWN

Effects of On-Line Hemodiafiltration(HDF) on Vascular Health in Chronic Hemodialysis Patients

NCT00532597

End Stage Renal Disease Hemodialysis

UNKNOWN PHASE4

Comparison of the Impact of Dialysis Treatment Type on Patient Survival

NCT00510549

End Stage Renal Disease

COMPLETED PHASE4

Impact of Dialysis Modality on Coagulation and Platelet Function

NCT04512131

Renal Replacement Therapy

COMPLETED

Comparison of Outcomes Between Hemodialysis and Peritoneal Dialysis Patients in a Multi-Ethnic Asian Population

NCT01587443

Stage 5 Chronic Kidney Disease Hemodialysis Peritoneal Dialysis

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

It has been considered that PD patients tended to be less anemic and require lower ESA dose than HD patients. In addition, it was also known that the level of oxidative stress and inflammatory cytokines tended to be lower in PD patients than HD patients. And hepcidin synthesis is markedly increased during inflammation. Altogether, Lower ESA requirement in PD patients may be associated with lower hepcidin level due to lower inflammatory state compared with HD patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

End-stage Renal Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Peritoneal dialysis

start PD

No interventions assigned to this group

Hemodialysis

start HD

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent
* Age 18 years or older
* Dialysis treatment was expected over 3 months
* In HD patients, regular hemodialysis 4 h a session more than two times a week
* In PD patients, over 2 exchange with more than 1.5 L solution

Exclusion Criteria

* Poorly controlled hypertension, i.e. sitting blood pressure exceeding 180/110 despite medication requiring hospitalization or interruption of ESA treatment
* Significant acute or chronic bleeding such as overt gastrointestinal bleeding within the previous 3 months
* Active malignant disease (except non-melanoma skin cancer and patients with malignant disease who have been disease-free for at least the 5 previous years are eligible)
* Acute infection
* Hemolysis
* Hemoglobinopathies (e.g. homozygous sickle-cell disease, thalassemia of all types)
* Megaloblastic anemia
* Platelet count \>500 x 109/L or \<100 x 109/L
* Pure red call aplasia
* Epileptic seizure during previous 3 months
* Women of childbearing potential without effective contraception
* Known hypersensitivity to recombinant human erythropoietin, polyethylene glycol
* Planned elective surgery during the study period except for cataract surgery or laser photocoagulation
* Life expectancy less than 12 month

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No